Published in Leukemia on February 28, 2014
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Cancer stem cells. N Engl J Med (2006) 9.63
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell (2010) 6.00
Translational control in cancer. Nat Rev Cancer (2010) 4.59
Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell (2013) 2.92
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A (2004) 2.32
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood (2009) 2.31
Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One (2009) 2.11
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem (2006) 1.76
Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem (2002) 1.70
Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem (2004) 1.69
The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int J Cancer (2007) 1.45
The cancerous translation apparatus. Curr Opin Genet Dev (2011) 1.38
Enantioselective photocycloaddition mediated by chiral Brønsted acids: asymmetric synthesis of the rocaglamides. J Am Chem Soc (2006) 1.32
Acute myeloid leukemia stem cells. Ann N Y Acad Sci (2005) 1.32
Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell (2012) 1.24
Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia (2002) 1.23
Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res (2007) 1.23
Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata. J Nat Prod (2010) 1.23
Nazarov cyclization initiated by peracid oxidation: the total synthesis of (+/-)-rocaglamide. J Am Chem Soc (2009) 1.21
Translation regulation as a therapeutic target in cancer. Cancer Res (2012) 1.14
Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol (2013) 1.12
Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep (2012) 1.12
Targeting translation dependence in cancer. Oncotarget (2011) 1.09
Leukemia stem cells in 2010: current understanding and future directions. Blood Rev (2011) 1.09
Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin Cancer Res (2012) 1.04
Inhibitors of translation initiation as cancer therapeutics. Future Med Chem (2009) 1.02
Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ (2010) 1.02
Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets (2010) 1.02
c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia (2008) 0.96
Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org Lett (2013) 0.95
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J (2011) 0.95
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death Dis (2012) 0.94
Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ (2009) 0.89